Drug Trial Radar · NCT06549400
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
176
Planned (sponsor's estimate)
Start
Sep 12, 2025
Primary completion
May 29, 2028
Study completion Jul 6, 2028
Sponsor
- Lead sponsor
- Lupin Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Lupin Atlantis Holdings S.A.
- First posted
- Aug 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension study intended to evaluate the long-term safety and efficacy of mexiletine PR in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed the parent study MEX-DM-302.
Conditions
- Myotonic Dystrophy
Interventions
Mexiletine granules for prolonged-release oral suspensionDrug
Mexiletine PR
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the long-term efficacy of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2) who have completed MEX-DM-302 study.Time frame: 78 weeks
Locations
6 sites in 6 countries. Site status is shown where the registry gives one.
Laboratory for Muscle Diseases and Neuropathies
Leuven, Belgium
Aarhus University Hospital
Aarhus, Denmark
Ludug-Maximilians University
München, Germany
Azienda Ospedaliera Universitaria Policlinico Tor Vergata
Rome, Italy
University Hospital of Madrid
Madrid, Spain
University College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.